Future studies are necessary to determine the exact molecular mechanisms underlying rs433903 and whether this variant is causally implicated in CAD through mechanisms of SGEF to further establish SGEF as a new candidate target for therapy. This evidence concerns the gene ARHGEF26 and coronary artery disorder.